Specifically preventing degradation of individual NPs, combination of neprilysin inhibitors with particular peptidase-resistant designer NPs37 or even with pharmacological tools modulating PDE2 activity38,39 could be considered as new therapeutic options for cardiac disease. The gene discussed is MME; the disease is heart disorder.